Aging remains one of biology's most complex puzzles, and it is the single greatest risk factor for neurodegenerative diseases like Alzheimer's. Recent research supported by the National Institute on Aging is shedding light on senolytic drugs, which target and eliminate senescent cells that accumulate with age. Research from Senolytics Research indicates that these drugs may not only alleviate age-related decline but also potentially modify the course of Alzheimer's disease. As a science writer, I find this development thrilling. Anti-aging therapies are no longer science fiction; they are real molecules being tested in clinical trials. However, we must temper our enthusiasm with caution. The road from lab to clinic is long, and we need robust evidence of safety and efficacy in humans. Yet, the idea that we might slow aging and prevent Alzheimer's is a paradigm shift in medicine. Sweden's healthcare system, with its focus on innovation and preventive care, could be an early adopter of these therapies. For now, I'll keep a close eye on the trials, hopeful that we are witnessing the dawn of a new era in geroscience.